ECSP14013132A - Anticuerpos anti-psgl-1 y usos de los mismos - Google Patents

Anticuerpos anti-psgl-1 y usos de los mismos

Info

Publication number
ECSP14013132A
ECSP14013132A ECSP14013132A ECSP14013132A EC SP14013132 A ECSP14013132 A EC SP14013132A EC SP14013132 A ECSP14013132 A EC SP14013132A EC SP14013132 A ECSP14013132 A EC SP14013132A
Authority
EC
Ecuador
Prior art keywords
antibodies
psgl
same
cells
here
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjaya Singh
Tobias Litzenburger
Stefan Bassarab
Barbara Enenkel
Patrick Garidel
Heidrun Schott
Original Assignee
Abgenomics Cooperatief Ua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenomics Cooperatief Ua filed Critical Abgenomics Cooperatief Ua
Publication of ECSP14013132A publication Critical patent/ECSP14013132A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Abstract

Aquí se proporciona, en un aspecto, anticuerpos que se unen inmunoespecíficamente a PSGL-1, polinucleótidos que comprenden secuencias de nucleótido que codifican a tales anticuerpos, y los vectores de expresión y células huésped para producir a tales anticuerpos. También se proveen aquí los kits y las composiciones farmacéuticas que comprenden los anticuerpos que se unen específicamente a PSGL-1, así como los métodos para tratar un desorden o enfermedad causado por o asociado con la proliferación aumentada y/o cantidades aumentadas de células T activadas usando los anticuerpos aquí descritos.
ECSP14013132 2011-06-13 2014-01-13 Anticuerpos anti-psgl-1 y usos de los mismos ECSP14013132A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161496249P 2011-06-13 2011-06-13

Publications (1)

Publication Number Publication Date
ECSP14013132A true ECSP14013132A (es) 2015-04-30

Family

ID=47357432

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013132 ECSP14013132A (es) 2011-06-13 2014-01-13 Anticuerpos anti-psgl-1 y usos de los mismos

Country Status (20)

Country Link
US (3) US20130209449A9 (es)
EP (2) EP2718325A4 (es)
JP (1) JP6180408B2 (es)
KR (1) KR102103036B1 (es)
CN (3) CN116063522A (es)
AU (1) AU2012271845B2 (es)
BR (1) BR112013031892A2 (es)
CA (1) CA2838952C (es)
CL (1) CL2013003570A1 (es)
CO (1) CO6940376A2 (es)
EC (1) ECSP14013132A (es)
IL (2) IL229844B (es)
MX (1) MX358447B (es)
NZ (1) NZ619524A (es)
RU (1) RU2650817C2 (es)
SG (1) SG10201604767TA (es)
TW (1) TWI643872B (es)
UA (1) UA114712C2 (es)
WO (1) WO2012174001A1 (es)
ZA (1) ZA201400209B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
JP5710854B2 (ja) 2004-05-11 2015-04-30 アブゲノミクス コーペラティフ ユー．エー． Ｔ細胞死誘導エピトープ
NZ619524A (en) 2011-06-13 2016-10-28 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies and uses thereof
EP4079324A1 (en) * 2014-07-08 2022-10-26 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof
TWI753875B (zh) * 2016-01-08 2022-02-01 美商美國全心醫藥生技股份有限公司 四價抗psgl-1抗體及其用途
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
KR102630011B1 (ko) 2017-01-11 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
TWI788321B (zh) * 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
JP7211961B2 (ja) 2017-03-14 2023-01-24 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
JP2021531007A (ja) 2018-07-20 2021-11-18 ピエール、ファーブル、メディカマン Ｖｉｓｔａに対する受容体
CN113667015B (zh) * 2021-08-20 2022-10-11 北京康特泊瑞生物医药科技股份公司 靶向psgl-1蛋白的抗体及其用途
WO2023091958A1 (en) * 2021-11-17 2023-05-25 Altrubio Inc. Methods of using anti-psgl-1 antibodies in combination with jak inhibitors to treat t-cell mediated inflammatory diseases or cancers
WO2024057232A1 (en) * 2022-09-13 2024-03-21 Tetherex Pharmaceuticals Corporation Antibodies, compositions, and methods of treatment

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
ES2131107T3 (es) 1992-03-17 1999-07-16 Novartis Ag Anticuerpos obtenidos mediante ingenieria genetica.
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5710123A (en) 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
JPH08506017A (ja) 1993-01-25 1996-07-02 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ドメインの交換によるキメラｌ‐およびｐ‐セレクチン、ならびにそれらの使用
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
JPH11510543A (ja) 1995-08-03 1999-09-14 ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ ペプチド及びセレクチン介在炎症のｏ−グリカン阻害剤
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
CA2347119A1 (en) 1998-10-30 2000-05-11 Genetics Institute, Inc. Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
JP2003534291A (ja) 2000-05-19 2003-11-18 ザ センター フォー ブラッド リサーチ インク Ｐ−セレクチン活性の変調による止血障害の診断及び治療方法
AU2000274809A1 (en) 2000-09-12 2002-03-26 Genetics Institute Llc Inhibition of stenosis or restenosis by p-selectin antagonists
CN100347194C (zh) 2000-12-29 2007-11-07 萨文特医药公司 分离的包括含硫酸根部分的表位的分子,抗这样的表位的抗体,和它们的应用
US20040001839A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
AU2003263764A1 (en) 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
CA2531283A1 (en) 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
RU2377254C2 (ru) * 2003-12-25 2009-12-27 Кирин Фарма Кабусики Кайся Мутанты анти-cd40 антитела
EP1720996A4 (en) * 2004-02-13 2007-03-21 Immunomedics Inc RECOMBINANT CYTOTOXIC RASES CONTAINING FUSION PROTEINS
ES2403055T3 (es) * 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
JP5710854B2 (ja) 2004-05-11 2015-04-30 アブゲノミクス コーペラティフ ユー．エー． Ｔ細胞死誘導エピトープ
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI380996B (zh) * 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2008011348A2 (en) * 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
CN103554263B (zh) * 2007-03-22 2016-09-28 健泰科生物技术公司 结合膜结合的IgE的凋亡性抗IgE抗体
AU2008234248C1 (en) * 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
AU2008255352B2 (en) * 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
BRPI0812400A2 (pt) 2007-06-05 2014-10-29 Univ Yale Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
EP2190480A4 (en) * 2007-08-28 2013-01-23 Biogen Idec Inc ANTI-IGR-1R ANTIBODIES AND ITS USES
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20110086366A1 (en) * 2008-02-22 2011-04-14 Genmab A/S Methods for assessing the risk of adverse events upon treatment with igg4 antibodies
EP3388527A1 (en) * 2008-05-15 2018-10-17 Tetherex Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
WO2010102792A2 (en) * 2009-03-12 2010-09-16 Imed Ab Human antibodies against human fas and their use
WO2011014438A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
NZ619524A (en) 2011-06-13 2016-10-28 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies and uses thereof
MX2016017117A (es) 2014-06-20 2018-01-12 Abgenomics Int Inc Conjugados de anticuerpo her2-farmaco.

Also Published As

Publication number Publication date
CA2838952A1 (en) 2012-12-20
CL2013003570A1 (es) 2014-08-22
CN108892726A (zh) 2018-11-27
NZ619524A (en) 2016-10-28
IL287270A (en) 2021-12-01
US20130209449A9 (en) 2013-08-15
JP6180408B2 (ja) 2017-08-16
US20130251708A1 (en) 2013-09-26
EP2718325A1 (en) 2014-04-16
AU2012271845B2 (en) 2017-07-27
CO6940376A2 (es) 2014-05-09
CA2838952C (en) 2020-11-24
KR20140066153A (ko) 2014-05-30
MX2013014814A (es) 2014-07-22
CN116063522A (zh) 2023-05-05
MX358447B (es) 2018-08-21
RU2013158083A (ru) 2015-09-20
TWI643872B (zh) 2018-12-11
BR112013031892A2 (pt) 2016-11-22
CN103732626A (zh) 2014-04-16
EP2718325A4 (en) 2015-03-11
IL229844B (en) 2022-02-01
AU2012271845A1 (en) 2014-01-23
EP3925978A1 (en) 2021-12-22
US20130011391A1 (en) 2013-01-10
JP2014519524A (ja) 2014-08-14
KR102103036B1 (ko) 2020-04-22
UA114712C2 (uk) 2017-07-25
ZA201400209B (en) 2020-05-27
TW201302791A (zh) 2013-01-16
US20210395383A1 (en) 2021-12-23
WO2012174001A1 (en) 2012-12-20
SG10201604767TA (en) 2016-08-30
RU2650817C2 (ru) 2018-04-17
US11897964B2 (en) 2024-02-13

Similar Documents

Publication Publication Date Title
ECSP14013132A (es) Anticuerpos anti-psgl-1 y usos de los mismos
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
ECSP17041865A (es) Anticuerpos anti-cd47 y usos de los mismos
CU20140091A7 (es) Compuestos de imidazopirrolidinona
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
AR091837A1 (es) Compuestos para inmunoterapia dirigida
CL2014003355A1 (es) Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros.
UY34100A (es) INMUNOCONJUGADOS DEL PROFARMACO seco-MGBA, COMPOSICIONES Y MÉTODOS PARA PREPARARLOS, Y SUS USOS
AR094896A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
AR088171A1 (es) Anticuerpos anti-erbb3 y usos de los mismos
CR20150370A (es) Compuestos antivirales
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
EA202190619A1 (ru) Противовирусные соединения
BR112016013493A2 (pt) molécula de ácido nucleico, composição, vacina, e, métodos para prevenção de uma doença em um indivíduo com necessidade da mesma e para tratamento de uma doença em um indivíduo com necessidade do mesmo
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
AR090056A1 (es) Anticuerpos anti-cxcr3
AR087608A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
AR089178A1 (es) Anticuerpos anti-il-36r
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
BR112015012987A2 (pt) composições compreendendo anticorpos anti-cd38 e lenalidomida
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
UY33931A (es) Agentes de union biespecificos
CL2014003130A1 (es) Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune.